Codexis to Offer High-Performance Enzymes for Diagnostics Markets
January 06 2017 - 7:00AM
Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company,
announces that it will offer high-performance enzymes for customers
using next generation sequencing (NGS) and polymerase chain
reaction (PCR/qPCR) for in vitro molecular diagnostic
applications. Codexis’ first proprietary enzyme for this
market will target improved library preparation for NGS users, and
is expected to be available in beta-test format by the second
quarter of 2017.
“Enzymes are critical to the sensitivity and reliability of NGS
and PCR analyses,” said Michael Aldridge, Codexis Senior Vice
President, Corporate & Strategic Development. “Historically,
NGS and PCR work-flows relied on only modestly engineered
enzymes. However, as users push NGS and PCR into new, more
demanding applications, such as liquid biopsy and personalized
medicine samples, more capable enzymes are required.
“Our CodeEvolver® protein engineering platform technology is
able to rapidly deliver novel enzymes with dramatically enhanced
performance characteristics,” Aldridge added. “We are
confident that our enzymes can improve analytical efficiency,
processivity and fidelity while also reducing bias. In less than a
year, our CodeEvolver® platform technology has engineered an enzyme
that improves library preparation steps for NGS.”
“This has been an outstanding self-directed R&D investment
for Codexis,” said John Nicols, Codexis President and Chief
Executive Officer. “Today’s announcement signifies our first
effort to offer improved, proprietary Codexis enzymes to users in
the established industrial enzyme market and underscores our
ability to continue to develop differentiated and value-creating
proteins in new enzyme markets, alongside existing applications in
pharmaceutical manufacturing, biologic drug discovery and food
ingredient production.”
About CodeEvolver® Protein Engineering Platform
Technology
Codexis’ proprietary CodeEvolver® protein engineering platform
technology enables the rapid development of custom-designed enzymes
that are highly optimized for a specific function. The CodeEvolver®
platform technology is comprised of proprietary methods for the
optimization of proteins through the design and generation of
diverse genetic libraries, automated screening techniques,
algorithms for the interpretation of screening data and predictive
modelling. The Codexis CodeEvolver® platform technology is
covered by approximately 200 issued patents and pending patent
applications worldwide.
About Codexis, Inc.
Codexis, Inc. is a leading protein engineering company that
applies its technology to the development of biocatalysts for
commercial manufacture of pharmaceuticals and fine chemicals.
Codexis’ proven technology enables implementation of biocatalytic
solutions to meet customer needs for rapid, cost-effective and
sustainable manufacturing. For more information, see
www.codexis.com.
Forward-Looking Statements
This press release contain forward-looking statements relating
to Codexis’ anticipated offering of enzymes for NGS and PCR/qPCR
for in vitro molecular diagnostic applications, the target of
Codexis’ first enzyme for this market and the expected timing of
the availability of the beta-test format, the CodeEvolver® protein
engineering platform technology’s ability to rapidly deliver novel
enzymes with dramatically enhanced performance characteristics and
these enzymes’ ability to improve analytical efficiency,
processivity and fidelity while also reducing bias, the ability of
Codexis’ enzyme to improve library preparation steps for NGS,
Codexis’ efforts to offer improved, proprietary Codexis enzymes to
users in the established industrial enzyme market, and Codexis’
ability to continue to develop differentiated and value-creating
proteins in new enzyme markets, alongside existing applications in
pharmaceutical manufacturing, biologic drug discovery and food
ingredient production. You should not place undue reliance on
these forward-looking statements because they involve known and
unknown risks, uncertainties and other factors that are, in some
cases, beyond Codexis’ control and that could materially affect
actual results. Factors that could materially affect actual results
include Codexis’ dependence on its licensees and collaborators;
Codexis’ dependence on a limited number of products and customers
in its pharmaceutical business; potential adverse effects to
Codexis’ business if its customers’ pharmaceutical products are not
received well in the markets; Codexis’ ability to deploy its
technology platform in new market spaces; Codexis’ dependence on
key personnel; Codexis’ ability to compete may decline if it loses
some of its intellectual property rights; third party claims that
Codexis infringes third party intellectual property rights; and
Codexis could face increased competition if third parties
misappropriate Codexis biocatalysts. Additional factors that could
materially affect actual results can be found in Codexis’ Annual
Report on Form 10-K filed with the Securities and Exchange
Commission on March 8, 2016 and in Codexis’ Quarterly Report on
Form 10-Q filed with the Securities and Exchange Commission on
November 8, 2016, including, in each case, under the caption “Risk
Factors,” as well as Codexis’ other current and periodic reports
filed with the Securities and Exchange Commission. Codexis
expressly disclaims any intent or obligation to update these
forward-looking statements, except as required by law.
Codexis Contacts: Gordon SangsterChief
Financial Officer650-421-8115gordon.sangster@codexis.com
Investors LHA Jody Cain, 310-691-7100
jcain@lhai.com
Codexis (NASDAQ:CDXS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Codexis (NASDAQ:CDXS)
Historical Stock Chart
From Apr 2023 to Apr 2024